Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.19 USD
Change Today +0.0493 / 1.57%
Volume 11.3K
VCEL On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 1:34 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

vericel corp (VCEL) Snapshot

Open
$3.08
Previous Close
$3.14
Day High
$3.20
Day Low
$3.08
52 Week High
03/24/15 - $4.35
52 Week Low
09/23/14 - $2.55
Market Cap
75.9M
Average Volume 10 Days
44.5K
EPS TTM
$-1.15
Shares Outstanding
23.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERICEL CORP (VCEL)

Related News

No related news articles were found.

vericel corp (VCEL) Related Businessweek News

No Related Businessweek News Found

vericel corp (VCEL) Details

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.

187 Employees
Last Reported Date: 08/12/15
Founded in 1989

vericel corp (VCEL) Top Compensated Officers

Chief Executive Officer, President, Treasurer...
Total Annual Compensation: $519.6K
Chief Financial Officer, Vice President of Co...
Total Annual Compensation: $204.2K
Chief Operating Officer
Total Annual Compensation: $337.7K
Compensation as of Fiscal Year 2014.

vericel corp (VCEL) Key Developments

Vericel Corporation Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2015

Vericel Corporation announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $13,590,000 against $4,432,000 a year ago. Loss from operations was $2,265,000 against $8,522,000 a year ago. Net loss was $2,152,000 or $0.16 per basic and diluted share against $4,638,000 or $0.94 per basic and diluted share a year ago. Material expenditures not impacting the operating loss for the quarter include $1.2 million in capital expenditures related to the integration and upgrade of new and existing information technology systems. For the six months, the company reported total revenues of $24,439,000 against $4,432,000 a year ago. Loss from operations was $6,837,000 against $13,166,000 a year ago. Net loss was $7,014,000 or $0.43 per basic and diluted share against $10,633,000 or $2.18 per basic and diluted share a year ago.

Vericel Corporation, Q2 2015 Earnings Call, Aug 12, 2015

Vericel Corporation, Q2 2015 Earnings Call, Aug 12, 2015

Vericel to Submit MACI Biologics License Application to U.S. Food and Drug Administration by Year-End of 2015

Vericel announced that following discussions with the U.S. Food and Drug Administration it plans to submit a Biologics License Application (BLA) by the end of 2015 for MACI for the treatment of focal chondral cartilage defects in the knee. MACI (matrix-applied characterized autologous cultured chondrocytes) is a third-generation autologous chondrocyte implantation (ACI) product for the treatment of cartilage defects in the knee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCEL:US $3.19 USD +0.0493

VCEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.13 USD 0.00
Caladrius Biosciences Inc $1.65 USD +0.11
Cesca Therapeutics Inc $0.70 USD +0.02
Cytori Therapeutics Inc $0.38 USD +0.016
Nuo Therapeutics Inc $0.08 USD +0.0204
View Industry Companies
 

Industry Analysis

VCEL

Industry Average

Valuation VCEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERICEL CORP, please visit www.aastrom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.